Poseida Therapeutics

General Information


We are a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac DNA Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. 

Employees: 149
Founded: 2014
Contact Information
Address 9390 Towne Centre Drive, Suite 200, San Diego, California 92121, US
Phone Number 858-779-3100
Web Address http://www.poseida.com
View Prospectus: Poseida Therapeutics
Financial Information
Market Cap $989mil
Revenues $0 mil (last 12 months)
Net Income $-102.0 mil (last 12 months)
IPO Profile
Symbol PSTX
Exchange NASDAQ
Shares (millions): 14.0
Price range $16.00 - $16.00
Est. $ Volume $224.0 mil
Manager / Joint Managers BofA Securities/ Piper Sandler/ William Blair
CO-Managers -
Expected To Trade: 7/10/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change